Pyrilutamide, also known as KX-826, is a high-affinity silent antagonist of the androgen receptor. It is being developed by Kintor Pharmaceutical for the treatment of androgenetic alopecia and acne.
In 2021, Kintor Pharmaceutical completed a phase-2 clinical trial of the drug in China. The results showed a statistically significant increase in non-vellus target area hair count with pyrilutamide treatment compared to placebo.
What is pyrilutamide?
Buy pyrilutamide is a topical androgen receptor antagonist currently in development by Kintor Pharmaceutical for the treatment of male and female pattern hair loss. It works by blocking the activity of androgens in hair follicles, thus preventing the conversion of testosterone to DHT.
Suzhou Kintor Pharmaceutical is a clinical-stage drug company developing innovative small molecules and biological therapeutics. The company focuses on androgen receptor-related diseases where effective therapies are unavailable. Its product portfolio includes pyrilutamide, KX-826, GT20029, Destorsertib, and others.
In the US, pyrilutamide is in phase II trials for androgenetic alopecia. According to GlobalData, a leading provider of drug pipeline and clinical trial data analysis, the compound is expected to enter phase 3 for this indication by 2021 if it performs well in its ongoing China-based trials. It would be the first-in-class topical androgen receptor antagonist to be developed for AGA.
How does pyrilutamide work?
buy pyrilutamide from MV Supplements works by inhibiting the formation of testosterone and DHT in the hair follicle. It also blocks the binding of androgens to the hair follicle receptor, which causes hair growth to slow down or stop completely.
Kintor Pharmaceutical Ltd recently announced the US phase 2 clinical trial results for its androgen receptor antagonist pyrilutamide. It’s also known as KX-826, and it’s being developed for both male and female pattern baldness.
The phase 2 trial was a randomized, double-blind, vehicle-controlled study that observed changes in non-vellus hair counts over a 6 month period. Based on the results, the drug was shown to be effective in reducing AGA.
The next step is a phase 3 trial, which is expected to start in 2021. If pyrilutamide proves to be an effective AGA treatment, it may replace existing treatments like finasteride and dutasteride. It’s likely to have similar effectiveness but less side effects than the current options. We’ll keep you updated if any new information becomes available.
How long does pyrilutamide last?
Pyrilutamide is an androgen receptor antagonist that works to block the formation of DHT in hair follicles. It is undergoing clinical trials to treat androgenetic alopecia (pattern hair loss). Its topical formulation has the potential to be a powerful alternative to finasteride.
Kintor Pharmaceuticals is conducting a phase 2 US trial of its androgen receptor-blocking drug, pyrilutamide. The trial is a randomized, placebo-controlled, parallel-group, dose-escalation study. The primary objective of the study is to evaluate the safety and pharmacokinetics of pyrilutamide applied topically twice daily.
The company also has a phase III study of GT20029, another androgen receptor-blocking drug, planned to start next year (2021). GT20029 is different from pyrilutamide in that it degrades androgen receptors.
There are anecdotal reports of pyrilutamide having a positive effect on androgenetic alopecia on social media, but it’s hard to draw firm conclusions from these at this stage. Some people report quitting due to side effects, others say they experienced moderate hair growth, and one guy reported completely regrowing his hair with photos to back it up.
Where can I buy pyrilutamide?
Pyrilutamide is a new compound developed by Kintor Pharmaceuticals for the treatment of hair loss. It works by blocking testosterone and DHT from binding to the androgen receptor in the hair follicle. It does not decrease systemic androgen levels like oral 5-alpha reductase inhibitors and does not appear to cause adverse drug reactions such as decreased libido or erectile dysfunction.
It is currently in phase II clinical trials for androgenic alopecia. Kintor Pharmaceuticals is a biotechnology company that discovers and develops small molecule therapeutics. Its development programs include Proxalutamide, KX-826, ALK-1, GT-20029, and Destorsertib. It also provides clinical research services and carters to clients in Taiwan, Hong Kong, Brazil, and the US.
The drug is undergoing phase II clinical trials for androgenic baldness in the US. GlobalData is tracking its progress and has created drug-specific PTSR and LoA reports for it. To find out more, buy the report here. You can see how other drugs in this disease area are performing based on their phase transition and likelihood of approval scores.